ATE522507T1 - Montelukast in fester phase - Google Patents

Montelukast in fester phase

Info

Publication number
ATE522507T1
ATE522507T1 AT04765940T AT04765940T ATE522507T1 AT E522507 T1 ATE522507 T1 AT E522507T1 AT 04765940 T AT04765940 T AT 04765940T AT 04765940 T AT04765940 T AT 04765940T AT E522507 T1 ATE522507 T1 AT E522507T1
Authority
AT
Austria
Prior art keywords
montelukast
compound
fixed phase
formula
formulated
Prior art date
Application number
AT04765940T
Other languages
English (en)
Inventor
Arjanne Overeem
Den Heuvel Dennie Van
Original Assignee
Synhton B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522507(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synhton B V filed Critical Synhton B V
Application granted granted Critical
Publication of ATE522507T1 publication Critical patent/ATE522507T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04765940T 2003-10-10 2004-10-08 Montelukast in fester phase ATE522507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50995703P 2003-10-10 2003-10-10
PCT/EP2004/011430 WO2005040123A1 (en) 2003-10-10 2004-10-08 Solid-state montelukast

Publications (1)

Publication Number Publication Date
ATE522507T1 true ATE522507T1 (de) 2011-09-15

Family

ID=34520017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765940T ATE522507T1 (de) 2003-10-10 2004-10-08 Montelukast in fester phase

Country Status (12)

Country Link
US (1) US7553853B2 (de)
EP (1) EP1678139B1 (de)
JP (2) JP2007508271A (de)
AT (1) ATE522507T1 (de)
AU (1) AU2004283832B2 (de)
CA (1) CA2541994A1 (de)
ES (1) ES2371549T3 (de)
IL (1) IL174758A (de)
NO (1) NO20062098L (de)
PT (1) PT1678139E (de)
WO (1) WO2005040123A1 (de)
ZA (1) ZA200602837B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
ES2371549T3 (es) 2003-10-10 2012-01-05 Synthon B.V. Montelukast en estado sólido.
EP1709001A2 (de) * 2004-01-28 2006-10-11 Pliva Istrazivanje i Razvoj d.o.o. Feste formen von montelukastsäure
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
EP1760077A1 (de) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Polymorphe Formen vonMontelukast freie Säure
CA2554927A1 (en) 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
CA2563776A1 (en) 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
US9149472B2 (en) * 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
EP1817289A1 (de) * 2004-11-30 2007-08-15 Medichem, S.A. Neues verfahren zur herstellung einesleukotrienantagonisten
WO2006064269A2 (en) * 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
ES2358923T3 (es) 2005-07-05 2011-05-16 Teva Pharmaceutical Industries, Ltd. Purificación de montelukast.
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
EP1803457A1 (de) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmazeutische Zubereitung, welche Montelukast enthält
PT1976522E (pt) * 2005-12-30 2013-09-09 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica contendo montelucaste
EP1818057B1 (de) * 2006-02-09 2010-04-21 Teva Pharmaceutical Industries Ltd. Stabile pharmazeutische Zubereitungen von Montelukast-Natrium
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
EP1886998A1 (de) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
SI22382A (sl) * 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
WO2008062478A2 (en) * 2006-11-20 2008-05-29 Manne Satyanarayana Reddy Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
AU2008316283A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd Inhalation compositions comprising montelukast acid and a PDE-4 inhibitor or an inhaled corticosteroid
WO2009098271A1 (en) * 2008-02-06 2009-08-13 Farmaprojects, S.A. Process for the purification of montelukast by the preparation of acid addition salts and tert-amylamine salt
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2287154A1 (de) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Effiziente Synthese zur Herstellung von Montelukast
HUE026633T2 (en) 2010-02-26 2016-06-28 Toray Industries Covered solid preparation
EP2552892A1 (de) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP3134076A4 (de) 2014-04-25 2017-12-20 R.P. Scherer Technologies, LLC Stabile montelukast-lösung
KR20210042412A (ko) 2018-09-06 2021-04-19 주식회사 이노파마스크린 천식 또는 파킨슨병 치료를 위한 방법 및 조성물
CN111307979A (zh) * 2020-03-14 2020-06-19 鲁南制药集团股份有限公司 一种孟鲁司特钠及其制剂的有关物质检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2053216C (en) * 1990-10-12 2003-04-08 Michel L. Belley Saturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2053209C (en) * 1990-10-12 1998-12-08 Michel L. Belley Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
CN1420113A (zh) * 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
WO2003066598A1 (en) * 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
ATE540926T1 (de) 2003-06-06 2012-01-15 Morepen Lab Ltd Verbessertes verfahren zur herstellung von montelukastsäure natriumsalz in amorpher form
ES2371549T3 (es) 2003-10-10 2012-01-05 Synthon B.V. Montelukast en estado sólido.
WO2005074935A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor

Also Published As

Publication number Publication date
ZA200602837B (en) 2007-09-26
AU2004283832A1 (en) 2005-05-06
EP1678139A1 (de) 2006-07-12
EP1678139B1 (de) 2011-08-31
IL174758A0 (en) 2006-08-20
JP2007508271A (ja) 2007-04-05
JP2012072149A (ja) 2012-04-12
US20050107426A1 (en) 2005-05-19
IL174758A (en) 2012-09-24
PT1678139E (pt) 2011-11-28
US7553853B2 (en) 2009-06-30
ES2371549T3 (es) 2012-01-05
AU2004283832B2 (en) 2011-04-07
NO20062098L (no) 2006-05-10
WO2005040123A1 (en) 2005-05-06
CA2541994A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
ATE522507T1 (de) Montelukast in fester phase
TW200616976A (en) Pyrimidine derivatives
LUC00155I2 (de)
TW200738241A (en) Pyridazine derivatives
TW200626558A (en) Indazolone derivatives
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
AUPR213700A0 (en) Antiviral agents
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
MX2010005824A (es) Derivados de aminotiazol.
TW200740764A (en) Pyrazolone derivatives
DE60217118D1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
BR0317749A (pt) Composto, composição farmacêutica, e, uso de um composto
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
ATE297910T1 (de) Retinoid x rezeptormodulatoren
EP1340755A4 (de) Mittel mit wirkung gegen helicobacter
ME01395B (de) Verfahren zur Herstellung von (1S)-4,5-Dimethoxy-1-(methylaminomethyl)-benzocyclobutan und deren Säureadditionssalze, sowie ihre Verwendung für die Synthese von Ivabradin und deren Säureadditionssalze von pharmazeutischen verträglichen Säure
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
MX2009003169A (es) Derivados de sulfonamida.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties